For a better experience, Read this story in our App
-823.16
-253.20
+ 50.00
+ 1,836.00
+ 414.00
-823.16
-253.20
-253.20
+ 50.00
+ 50.00
+ 1,836.00
Natco Pharma’s consolidated net profit declined 37 per cent to ₹132 crore in the third quarter ended December 31, 2024, as against ₹212 crore in the same period last year, on account of a decrease in formulation exports.
The total revenue of the Hyderabad-based company also fell to ₹651 crore in the quarter under review, compared to ₹795 crore in the same period last year.
“During the quarter, contribution from the export formulation business was lower. However, the Company expects healthy growth of business in the ensuing quarters,’‘ Natco said in a release.
The Board of Directors has declared a third interim dividend of ₹1.5 per equity share for FY 2024-25.
Published on February 12, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.